

1 **Association of lipid-lowering drugs with COVID-19 outcomes: A Mendelian**
2 **Randomization study**

3 Wuqing Huang, M.D., Ph.D ¹#, Jun Xiao, M.D., Ph.D ²#, Jianguang Ji, M.D., Ph.D ³,
4 Liang-Wan Chen, M.D., Ph.D ²

5 ¹ Department of Epidemiology and Health Statistics, School of Public Health, Fujian
6 Medical University, Fuzhou, Fujian, China.

7 ² Department of Cardiovascular Surgery, Fujian Medical University Union Hospital,
8 Fuzhou, China.

9 ³ Center for Primary Health Care Research, Department of Clinical Sciences Malmö, Lund
10 University, Sweden.

11 **# Contributed equally.**

12 **Short title:** Lipid-lowering drugs and COVID-19.

13 **Correspondence:** Liang-Wan Chen & Jianguang Ji

14 Liang-Wan Chen,

15 Fujian Medical University Union Hospital,

16 No. 29 Xinquan Road, Fuzhou City, 350001,

17 Fujian Province, China.

18 Email: chenliangwan@tom.com Telephone: +8613358255333

19 Jianguang Ji,

20 Center for Primary Health Care Research,

21 Jan Waldenströms gata 35, Skåne University Hospital, 205 02 Malmö, Sweden.

22 Email: Jianguang.ji@med.lu.se Telephone: +4640391382

23 **Word count:** 3855

- 1 **Disclosures:** The authors declare no conflict of interest.
- 2 **Acknowledgments:** We thank the patients and investigators who contributed to the
- 3 eQTLGen Consortium, GTEx Consortium, COVID-19 Host Genetics Initiative, Global
- 4 Lipids Genetics Consortium and CARDIoGRAMplusC4D Consortium.
- 5

1 **Abstract**

2 **Background** Lipid metabolism plays an important role in viral infections. Large cohort
3 study suggested a protective potential of lipid-lowering drugs in COVID-19 outcomes, but
4 the nature of observational study precludes it to draw a causal inference.

5 **Objectives** To assess the causal effect of lipid-lowering drugs (HMGCR inhibitors, PCSK9
6 inhibitors and NPC1L1 inhibitors) on COVID-19 outcomes using 2-sample Mendelian
7 Randomization (MR) study.

8 **Methods** We used two kinds of genetic instruments to proxy the exposure of lipid-lowering
9 drugs, including expression quantitative trait loci (eQTLs) of drugs target genes, and
10 genetic variants within or nearby drugs target genes associated with low-density lipoprotein
11 (LDL) cholesterol from genome-wide association study (GWAS). GWASs of COVID-19
12 outcomes (susceptibility, hospitalization and very severe disease) were obtained from the
13 COVID-19 Host Genetics Initiative. Summary-data-based MR (SMR) and inverse-
14 variance weighted MR (IVW-MR) were used to calculate the effect estimates.

15 **Results** SMR analysis found that a higher expression of HMGCR was associated with a
16 higher risk of COVID-19 hospitalization (OR=1.38, 95%CI=1.06-1.81; P=0.019).
17 Similarly, IVW-MR analysis observed a positive association between HMGCR-mediated
18 LDL cholesterol and COVID-19 hospitalization (OR=1.32, 95%CI=1.00-1.74; P=0.049).
19 No consistent evidence from both SMR and IVW-MR analyses was found for the
20 association of HMGCR inhibitors with COVID-19 susceptibility or very severe disease, or
21 for the association of PCSK9 inhibitors and NPC1L1 inhibitor with COVID-19 outcomes.

1 **Conclusions** In this 2-sample MR study, we found potential causal evidence that HMGCR
2 inhibitors could reduce the risk of COVID-19 hospitalization. Further research is needed
3 to explore the therapeutic role of statins for COVID-19.

4 **Keywords:** lipid-lowering drugs, COVID-19, Mendelian randomization.

5 **Abbreviations and Acronyms:** CI, confidence interval; eQTLs, expression quantitative
6 trait loci; GWAS, genome-wide association study; HEIDI, heterogeneity in dependent
7 instruments; HMGCR, HMG-CoA reductase; IVW-MR, inverse-variance weighted
8 Mendelian Randomization; LDL, low-density lipoprotein; MR-PRESSO, Mendelian
9 Randomization Pleiotropy RESidual Sum and Outlier; MAF, minor allele frequency;
10 NPC1L1, Niemann-Pick C1-Like 1; OR, odds ratio; PCSK9, Proprotein convertase
11 subtilisin/kexin type 9; SNP, single-nucleotide polymorphism; SMR, summary-data-based
12 Mendelian Randomization.

1 **Introduction**

2 The COVID-19 pandemic has caused millions of infections and deaths, which is caused by
3 a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
4 Lacking of drugs specifically targeted to SARS-CoV-2 infection has led to a great interest
5 to identify drugs that can be repurposed to reduce the infection and mortality of the disease.
6 Available studies have suggested an important role of lipid metabolism in viral infections,
7 including in the pathogenesis of SARS-CoV-2 infection (1). The plausible mechanisms
8 include the involvement of host lipids in the virus life cycle, the influence of cholesterol
9 on the immune cell functions, interfering with the mevalonate pathway, and so on (1). Such
10 evidence indicates the potential protective effect of lipid-lowering drugs against COVID-
11 19. HMG-CoA Reductase (HMGCR) inhibitors, known as statins, are the most commonly-
12 used class of lipid-lowering drugs, which have a couple of predominant merits, such as the
13 well-proven safety, low cost, and pleiotropic effects. Therefore, a number of observational
14 studies have investigated the association between statins and COVID-19 outcomes, but
15 generating mixed results (2-6). What's more, confounding bias and reverse causation
16 cannot be avoided in most of these studies.

17 Mendelian randomization (MR) study uses genetic variants as an instrument to perform
18 causal inference between an exposure and an outcome, which could determine whether an
19 observational association is consistent with a causal effect (7). Confounding bias can be
20 minimized in MR study because genetic variants are randomly assigned to the individual
21 at birth. Similarly, reverse causation can be avoided because genetic variants are assigned
22 prior to the development of disease.

1 Therefore, we performed 2-sample MR analysis in this study to test the association of
2 several FDA-approved lipid-lowering drugs (HMGCR inhibitors, PCSK9 inhibitors and
3 NPC1L1 inhibitors) with COVID-19 outcomes (susceptibility, hospitalization and very
4 severe disease).

5

6 **Methods**

7 **Study design**

8 This 2-sample MR study is based on publicly available summary-level data from genome-
9 wide association studies (GWASs) and expression quantitative trait loci (eQTLs) studies
10 (**Supplementary Table 1**). All these studies had been approved by the relevant
11 institutional review boards and participants had provided informed consents.

12 **Selection of genetic instruments**

13 Three classes of FDA-approved lipid-lowering drugs were included as exposures in this
14 study: HMGCR inhibitors (i.e., statins), proprotein convertase subtilisin/kexin type 9
15 (PCSK9) inhibitors (i.e., alirocumab and evolocumab), and niemann-Pick C1 like 1
16 (NPC1L1) inhibitor (i.e., ezetimibe).

17 As shown in **Table 1**, we used available eQTLs for drugs target genes (i.e., HMGCR,
18 PCSK9, NPC1L1) as the proxy of exposure to each lipid-lowering drug. The eQTLs
19 summary-level data was obtained from eQTLGen Consortium (<https://www.eqtlgen.org/>)
20 or GTEx Consortium V8 (<https://gtexportal.org/home/>). We identified common (minor
21 allele frequency (MAF) >1%) eQTLs single-nucleotide polymorphisms (SNPs)
22 significantly ($p < 5.0 \times 10^{-8}$) associated with the expression of HMGCR or PCSK9 in blood,

1 and the expression of NPC1L1 in adipose subcutaneous tissue as there are no eQTLs in
2 blood or other tissues available at a significance level for NPC1L1. Only cis-eQTLs were
3 included to generate genetic instruments in this study, which were defined as eQTLs within
4 1 Mb on either side of the encoded gene.

5 Secondly, to validate the observed association using the eQTLs as an instrument, we
6 additionally proposed an instrument by selecting SNPs within 100 kb windows from target
7 gene of each drug that were associated with LDL cholesterol level at a genome-wide
8 significance level ($p < 5.0 \times 10^{-8}$) to proxy the exposure of lipid-lowering drugs. A GWAS
9 summary data of LDL cholesterol levels from the Global Lipids Genetics Consortium was
10 used to identify these SNPs, where only common SNPs (MAF > 1%) were included (8).
11 Seven SNPs within 100 kb windows from HMGCR gene were selected for proxying
12 HMGCR inhibitors, 12 SNPs from PCSK9 gene identified for PCSK9 inhibitors, and three
13 SNPs from NPC1L1 gene selected for NPC1L1 inhibitor. To maximize the strength of the
14 instrument for each drug, SNPs used as instruments were allowed to be in low weak linkage
15 disequilibrium ($r^2 < 0.30$) with each other.

16 **Outcome sources**

17 GWAS summary-level data for COVID-19 outcomes were obtained from the COVID-19
18 Host Genetics Initiative V4 (<https://www.covid19hg.org/>) (9). The study population was
19 restricted to individuals with European ancestry, including meta-analyses of GWASs
20 containing up to 22 cohorts from 11 countries. GWAS from these cohorts used a model
21 adjusted for age, sex, age \times age, age \times sex, genetic principal components, and study-
22 specific covariates. A COVID-19 case was confirmed by lab or self-reported infections, or
23 electronic health records of infections. The susceptibility outcome was measured by

1 comparing COVID-19 cases and controls who did not have a history of COVID-19. The
2 hospitalized outcome was measured by comparing COVID-19 hospitalized cases and
3 controls who were never admitted to the hospital due to COVID-19, including individuals
4 without COVID-19. The severe disease outcome was measured by comparing COVID-19
5 cases who died or required respiratory support and controls without severe COVID-19,
6 including individuals without COVID-19. We included individuals without COVID-19 as
7 controls for all outcomes to decrease collider bias and allow for population-level
8 comparisons (10,11).

9 **Statistical analyses**

10 *Primary MR analysis*

11 Summary-data-based MR (SMR) method was applied to generate effect estimates when
12 using eQTLs as an instrument, which investigates the association between the expression
13 level of a gene and outcome of interest using summary-level data from GWAS and eQTL
14 studies (12). Allele harmonization and analysis were performed using SMR software,
15 version 1.03 (<https://cnsgenomics.com/software/smr/#Overview>). Inverse-variance
16 weighted MR (IVW-MR) method was used to combine effect estimates when using genetic
17 variants associated with LDL cholesterol level as an instrument. Allele harmonization and
18 analysis were conducted using the TwoSampleMR package in R software, version 4.1.0.

19 *Sensitivity analysis*

20 The strength of SNPs used as the instrument was assessed using the F-statistic, and we
21 included SNPs with an F-statistic of >10 to minimize weak instrument bias (13). Positive
22 control analyses were performed for validation of both genetic instruments. Since lowering

1 the level of LDL cholesterol is the well-proven effect of lipid-lowering drugs, we thus
2 examined the association of exposures of interest with LDL cholesterol level as positive
3 control study for the instrument from eQTLs. For the instrument from LDL cholesterol
4 GWAS, we performed positive control study by examining the association of exposures of
5 interest with coronary heart disease because coronary heart disease is the main indication
6 of lipid-lowering drugs.

7 For SMR method, the heterogeneity in dependent instruments (HEIDI) test was used to test
8 if the observed association between gene expression and outcome was due to a linkage
9 scenario, which was performed in the SMR software (12). As recommended by the authors,
10 the HEIDI test of $P < 0.01$ indicates that association is probably due to linkage (12). One
11 SNP could be related to the expression of more than one gene, leading to the presence of
12 horizontal pleiotropy. To assess the risk of horizontal pleiotropy, we identified other nearby
13 genes (within a 1Mb window) with significant association with the genetic instrumental
14 variant, and performed SMR analysis to examine if the expression of these genes was
15 related to the COVID-19 outcomes.

16 For IVW-MR method, we tested the heterogeneity by using a Cochran Q test, where $P < 0.05$
17 indicates the evidence of heterogeneity (14). MR-Egger regression and Mendelian
18 Randomization Pleiotropy RESidual Sum and Outlier (MR-PRESSO) analysis were used
19 to assess the potential horizontal pleiotropy of the SNPs used as instrument variants. In
20 MR Egger regression, the intercept term is a useful indication of directional horizontal
21 pleiotropy, where $P < 0.05$ indicates the evidence of horizontal pleiotropy (15). MR-
22 PRESSO analysis can identify horizontal pleiotropic outliers and provide adjusted

1 estimates, where $P < 0.05$ for Global test indicates the presence of horizontal pleiotropic
2 outliers (16). All these analyses were implemented in R software, version 4.1.0.

3 To account for multiple testing correction, Bonferroni correction was used to adjust the
4 thresholds of significance level, with a strong evidence of $P < 0.006$ (3 exposures and 3
5 outcomes) and a suggestive evidence of $0.006 \leq P < 0.05$.

6 **Results**

7 **Genetic instruments selection and COVID-19 outcomes**

8 A total of 168, 24, and 11 cis-eQTLs were identified from eQTLGen or GTEx Consortium
9 for drugs target gene HMGCR, PCSK9, and NPC1L1, respectively, and the most
10 significant cis-eQTL SNP was selected as a genetic instrument for target gene of each drug
11 (**Table 1, Supplementary Table 2**). A total of 7, 12, and 3 SNPs within or nearby gene
12 HMGCR, PCSK9, and NPC1L1 were selected from a GWAS summary data of LDL
13 cholesterol levels in the Global Lipids Genetics Consortium, respectively (**Table 1,**
14 **Supplementary Table 3**). F-statistics for all instrument variants were over 30, suggesting
15 that weak instrument bias can be minimized in our study (**Supplementary Table 2 and 3**).
16 Positive control study showed significant associations between exposure to each drug and
17 LDL cholesterol when using eQTLs-proposed instruments (**Supplementary Table 5**), as
18 well as between exposure to each drug and coronary heart disease when using LDL
19 cholesterol GWAS-proposed instruments (**Supplementary Table 6**), further ensuring the
20 efficacy of the selected genetic instruments.

21 From COVID-19 GWASs, a total of 14,134 cases and 1,284,876 controls were used to
22 explore the association with COVID-19 susceptibility, 6,406 cases and 902,088 controls

1 for COVID-19 hospitalization, and 3,886 cases and 622,265 controls for COVID-19 severe
2 disease (**Supplementary Table 1**).

3 **Primary analysis**

4 In **Figure 1 and Supplementary Table 2**, results from SMR analysis found a suggestive
5 evidence for the association of the increased expression of HMGCR gene in blood
6 (equivalent to a 1 standard deviation increase) with the higher risk of COVID-19
7 susceptibility (OR=1.30, 95%CI=1.05-1.61; P=0.017) and COVID-19 hospitalization
8 (OR=1.38, 95%CI=1.06-1.81; P=0.019), indicating that HMGCR inhibitors can lower the
9 risk of COVID-19 susceptibility and hospitalization. A suggestive evidence was observed
10 regarding the negative association between PCSK9 expression and risk of COVID-19
11 susceptibility (OR=0.84, 95%CI=0.73-0.97; P=0.02). No significant association was found
12 between the expression of NPC1L1 and COVID-19 outcomes.

13 In **Figure 2 and Supplementary Table 4**, IVW-MR analysis also found a suggestive
14 evidence for the association between HMGCR-mediated LDL cholesterol (equivalent to a
15 1-mmol/L increase) and the risk of COVID-19 hospitalization (OR=1.32, 95%CI=1.00-
16 1.74; P=0.049), further supporting the protective effect of HMGCR inhibitors against
17 COVID-19 hospitalization. A strong evidence was observed between NPC1L1-mediated
18 LDL cholesterol and risk of COVID-19 susceptibility (OR=2.02, 95%CI=1.30-3.13;
19 P=0.002). IVW-MR analysis did not provide any evidence for the association between
20 PCSK9-mediated LDL cholesterol and COVID-19 outcomes.

21 **Sensitivity analysis**

1 For SMR analysis, HEIDI test suggested that all observed associations were not due to a
2 linkage ($P > 0.01$), except for the association between HMGCR expression and COVID-19
3 susceptibility ($P = 0.009$) (**Supplementary Table 2**). We further examine if horizontal
4 pleiotropy was present in the association between HMGCR expression and COVID-19
5 outcomes by investigating if there was an association between the expression of nearby
6 genes which are significantly associated with the top eQTL SNP (instrument variant) of
7 HMGCR and COVID-19 outcomes. We identified six genes, including HMGCR, the
8 expression of which were associated with the instrument variant (**Supplementary Table**
9 **7**). Only four genes have available eQTLs at a genome-wide significance level ($p < 5.0 \times 10^{-8}$).
10 Among these four genes, only HMGCR expression was significantly related to COVID-
11 19 susceptibility and COVID-19 hospitalization, suggesting a small role of horizontal
12 pleiotropy in the observed associations (**Supplementary Table 8**).

13 For IVW-MR analysis, Cochran Q test did not found evidence of heterogeneity for all
14 reported results (All $P < 0.05$; **Supplementary Table 4**). Both the intercept term in MR-
15 Egger regression and MR-PRESSO analysis suggested that horizontal pleiotropy played a
16 small role in the reported results (All $P < 0.05$; **Supplementary Table 4**).

17 **Discussion**

18 The present MR study provided a suggestive evidence regarding the positive association
19 of the HMGCR expression and HMGCR-mediated LDL cholesterol level with the risk of
20 COVID-19 hospitalization, both of which together indicated a protective effect of HMGCR
21 inhibitors against COVID-19 hospitalization ($OR_{\text{instrument 1}} = 0.72$, $95\%CI = 0.55-0.95$; $OR_{\text{instrument 2}} = 0.76$,
22 $95\%CI = 0.57-1.00$). We found a suggestive evidence of the negative
23 association between PCSK9 expression and COVID-19 susceptibility, but which was not

1 supported when using LDL cholesterol GWAS as an instrument. A strong evidence was
2 observed for the protective effect of NPC1L1-mediated lower level of LDL cholesterol on
3 COVID-19 susceptibility, but there was no evidence for the association of NPC1L1
4 expression and COVID-19 outcomes.

5 Compared to develop a new drug, repurposing an old drug is much more economical and
6 time-saving, in particular, the importance is further highlighted during a pandemic.
7 COVID-19 pandemic has driven a number of studies of drug repurposing (17,18). The role
8 of lipid metabolism in viral infections has raised the interest regarding the possibility of
9 repurposing lipid-lowering drugs as anti-COVID-19 agents (1). As one of the most
10 commonly prescribed drugs, statins have received the greatest attention for their pleiotropic
11 effects, including lowering serum cholesterol, anti-inflammatory and immunomodulatory
12 properties and antithrombotic effect, all of which play a role in viral infections (1,17,19).
13 Emerging observational studies have investigated if statins might benefit patients with
14 COVID-19 (2-6). A largest retrospective cohort study including 13,981 patients admitted
15 to hospital due to COVID-19 suggested a significant reduction in 28-day all-cause
16 mortality by 42% in the group with statins than patients without statins (2). A meta-analysis
17 with 8,990 COVID-19 patients also found a 30% lower risk of fatal or severe disease (3).
18 However, a Danish nationwide cohort study with 4,842 COVID-19 patients and a meta-
19 analysis with 3,449 COVID-19 patients did not found the association between statins use
20 and improved COVID-19 outcomes (5,6). In addition, in these studies, considerable
21 differences in clinical characteristics cannot be avoided between patients with and without
22 statins, and causal inference is not allowed due to the retrospective nature of observational
23 studies.

1 As a genetic epidemiological method, MR study could overcome the limitations of
2 traditional observational studies. In this MR study, we used genetic variants related to
3 HMGCR expression or HMGCR-mediated LDL cholesterol as instruments to proxy the
4 exposure of statins. Both analyses found a suggestive evidence that statins could reduce
5 the risk of COVID-19 hospitalization, rather than COVID-19 susceptibility and very severe
6 outcome. Although strong evidence is lacking, these results provided a causal evidence
7 supporting the finding from the largest cohort study (2), which calls for additional
8 observational studies in different populations, mechanistic studies, and randomized
9 controlled studies to examine its potential effect against COVID-19. Besides, although no
10 association was found between NPC1L1 expression in adipose subcutaneous and COVID-
11 19 outcomes, there was a strong evidence of the association between NPC1L1-mediated
12 LDL cholesterol and COVID-19 susceptibility. The effect of NPC1L1 inhibitor on
13 COVID-19 susceptibility may be worth further studies as well.

14 **Study strengths**

15 The main strength of our study is the use of genetic instruments to proxy drug exposure,
16 which could minimize confounding bias and avoid reverse causation. Besides, we used two
17 different kinds of genetic instruments to proxy the studied drug, which contributes to
18 validate the effect estimates from each other. And a number of sensitivity analyses have
19 been performed to test the efficacy of genetic instruments and the assumptions of MR study.
20 In addition, we used large eQTL summary data of drugs target genes and GWAS summary
21 data of LDL cholesterol and COVID-19 outcomes, which could ensure statistical power.

22 **Study limitations**

1 This study has several limitations. Firstly, there are no available eQTLs in blood for
2 NPC1L1, so we were not allowed to explore the association between NPC1L1 expression
3 in blood and COVID-19 outcomes. Besides, there are no available eQTLs in lung for
4 HMGCR, which might provide more convincing evidence of the association between
5 HMGCR inhibitors and COVID hospitalization. Secondly, the effect of statins probably
6 varies between subgroups, for example, it may be more effective in patients with chronic
7 diseases (e.g., coronary heart disease). However, the use of summary-level data did not
8 allow us to perform subgroup analyses, so further MR study with individual-level data is
9 needed to provide more detailed information. Thirdly, the Bonferroni correction for
10 multiple tests suggests that we cannot rule out the false-positive possibility for the finding
11 of the protective effect of statins on COVID hospitalization. Fourthly, confounding bias
12 and/or horizontal pleiotropy cannot be completely excluded although we have performed
13 various sensitivity analyses to test the assumptions of MR study.

14 **Conclusions**

15 In conclusion, this MR study provided potential causal evidence for the association
16 between statins exposure and the reduced risk of COVID-19 hospitalization. Further
17 research is called to confirm the association and the underlying mechanisms.

18

19 **Author Contributors:** WH, JX, JJ, and LWC were responsible for the study concept and
20 design. WH and JX acquired the data. WH and JX did the statistical analysis and drafted
21 the manuscript, and all authors revised it for important intellectual content. WH and JX
22 contributed equally to the study.

References

1. Proto MC, Fiore D, Piscopo C et al. **Lipid homeostasis and mevalonate pathway in COVID-19: Basic concepts and potential therapeutic targets** Progress in lipid research, 82 (2021), pp.101099
2. Zhang XJ, Qin JJ, Cheng X et al. **In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19** Cell metabolism, 32 (2020), pp.176-187.e4
3. Kow CS, Hasan SS. **Meta-analysis of Effect of Statins in Patients with COVID-19** The American journal of cardiology, 134 (2020), pp.153-155
4. Gupta A, Madhavan MV, Poterucha TJ et al. **Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19** Nature communications, 12 (2021), pp.1325
5. Hariyanto TI, Kurniawan A. **Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection** Diabetes Metab Syndr, 14 (2020), pp.1613-1615
6. Butt JH, Gerds TA, Schou M et al. **Association between statin use and outcomes in patients with coronavirus disease 2019 (COVID-19): a nationwide cohort study** BMJ Open, 10 (2020), pp.e044421
7. Davies NM, Holmes MV, Davey Smith G. **Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians** BMJ (Clinical research ed), 362 (2018), pp.k601
8. Willer CJ, Schmidt EM, Sengupta S et al. **Discovery and refinement of loci associated with lipid levels** Nature genetics, 45 (2013), pp.1274-1283

9. **The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic** *European journal of human genetics : EJHG*, 28 (2020), pp.715-718
10. Griffith GJ, Morris TT, Tudball MJ et al. **Collider bias undermines our understanding of COVID-19 disease risk and severity** *Nature communications*, 11 (2020), pp.5749
11. Butler-Laporte G, Nakanishi T, Mooser V et al. **Vitamin D and COVID-19 susceptibility and severity in the COVID-19 Host Genetics Initiative: A Mendelian randomization study** *PLoS medicine*, 18 (2021), pp.e1003605
12. Zhu Z, Zhang F, Hu H et al. **Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets** *Nature genetics*, 48 (2016), pp.481-7
13. Burgess S, Thompson SG. **Avoiding bias from weak instruments in Mendelian randomization studies** *International journal of epidemiology*, 40 (2011), pp.755-64
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG. **Measuring inconsistency in meta-analyses** *BMJ (Clinical research ed)*, 327 (2003), pp.557-60
15. Burgess S, Thompson SG. **Interpreting findings from Mendelian randomization using the MR-Egger method** *European journal of epidemiology*, 32 (2017), pp.377-389
16. Verbanck M, Chen CY, Neale B, Do R. **Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases** *Nature genetics*, 50 (2018), pp.693-698

17. Fajgenbaum DC, Rader DJ. **Teaching Old Drugs New Tricks: Statins for COVID-19?** Cell metabolism, 32 (2020), pp.145-147
18. Gaziano L, Giambartolomei C, Pereira AC et al. **Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19** Nature medicine, 27 (2021), pp.668-676
19. Rubin R. **Could Statins Do More Than Lower Cholesterol in Patients With COVID-19?** Jama, 325 (2021), pp.2424-2425

Figure legends:

Figure 1. SMR association between expression of gene HMGCR, PCSK9, or NPC1L1 and COVID-19 outcomes.

Abbreviations and Acronyms: CI, confidence interval; HMGCR, HMG-CoA reductase; NPC1L1, Niemann-Pick C1-Like 1; OR, odds ratio; PCSK9, Proprotein convertase subtilisin/kexin type 9; SMR, summary-data-based Mendelian Randomization.

Figure 2. IVW-MR association between LDL cholesterol mediated by gene HMGCR, PCSK9, or NPC1L1 and COVID-19 outcomes.

Abbreviations and Acronyms: CI, confidence interval; HMGCR, HMG-CoA reductase; IVW-MR, inverse-variance weighted Mendelian Randomization; NPC1L1, Niemann-Pick C1-Like 1; OR, odds ratio; PCSK9, Proprotein convertase subtilisin/kexin type 9.

Perspectives

COMPETENCY IN MEDICAL KNOWLEDGE: A suggestive evidence indicates that statins use is causally associated with a reduced risk of COVID-19 hospitalization.

TRANSLATIONAL OUTLOOK: The protective effect of statins should be further confirmed in randomized controlled trials.

Central Illustration. Lipid-lowering drugs and COVID-19 outcomes.

Lipid metabolism plays an important role in the viral infections, indicating the potential to be repurposed against COVID-19. However, previous observational studies yielded inconsistent findings. The present 2-sample Mendelian randomization study provides a suggestive evidence for the causal relationship between statins use and lower risk of COVID-19 hospitalization, which could overcome the limitations of observational study (i.e., confounding bias and reverse causation).

Table 1. Information of genetic instruments.

Exposure	Genetic instruments	
	Genetic variants associated with mRNA expression levels (eQTLs)	Genetic variants associated with LDL cholesterol level
HMGCR inhibitors	168 common cis-eQTLs (MAF>1%) in blood for HMGCR gene ($P < 5.0 \times 10^{-8}$), top SNP: rs6453133	7 common SNPs (MAF>1%) in low linkage disequilibrium ($r^2 < 0.30$), associated with LDL cholesterol ($P < 5.0 \times 10^{-8}$), located within ± 100 kb windows from HMGCR region
PCSK9 inhibitors	24 common cis-eQTLs (MAF>1%) in blood for PCSK9 gene ($P < 5.0 \times 10^{-8}$), top SNP: rs472495	12 common SNPs (MAF>1%) in low linkage disequilibrium ($r^2 < 0.30$), associated with LDL cholesterol ($P < 5.0 \times 10^{-8}$), located within ± 100 kb windows from PCSK9 region
NPC1L1 inhibitors	11 common cis-eQTLs (MAF>1%) in adipose subcutaneous tissue for NPC1L1 gene ($P < 5.0 \times 10^{-8}$), top SNP: rs41279633	3 common SNPs (MAF>1%) in low linkage disequilibrium ($r^2 < 0.30$), associated with LDL cholesterol ($P < 5.0 \times 10^{-8}$), located within ± 100 kb windows from NPC1L1 region
Statistical analyses		
Primary analysis	Summary-data-based Mendelian Randomization	Inverse-variance weighted Mendelian Randomization
Sensitivity analyses	F-statistic Positive control analysis (LDL cholesterol used as outcome) Linkage disequilibrium test: HEIDI test Horizontal pleiotropy test: SMR association between expression of adjacent genes and outcome	F-statistic Positive control analysis (coronary heart disease used as outcome) Heterogeneity test: Cochran Q test Horizontal pleiotropy test: MR-Egger regression, MR-PRESSO test

Abbreviations and Acronyms: eQTLs, expression quantitative trait loci; GWAS, genome-wide association study; HEIDI, heterogeneity in dependent instruments; HMGCR, HMG-CoA reductase; IVW-MR, inverse-variance weighted Mendelian Randomization; LDL, low-density lipoprotein; MR-PRESSO, Mendelian Randomization Pleiotropy RESidual Sum and Outlier; MAF, minor allele frequency; NPC1L1, Niemann-Pick C1-Like 1; PCSK9, Proprotein convertase subtilisin/kexin type 9; SNP, single-nucleotide polymorphism; SMR, summary-data-based Mendelian Randomization.



